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BCL6  functions  as  a  transcriptional  repressor 
(Chang et al., 1996; Seyfert et al., 1996; Shaffer 
et al., 2000) in normal and malignant germinal 
center (GC) B cells, and belongs to the BTB/
POZ (Bric-à-brac, tramtrack, broad complex/
Pox virus zinc finger) zinc finger family of pro-
teins. In diffuse large B cell lymphomas (DLB-
CLs), BCL6 is frequently translocated into the Ig 
heavy or light chain loci (e.g., t(3;14)(q27;q32); 
Ye et al., 1993). During normal B cell devel-
opment, BCL6 expression was only found in 
GC B cells (Cattoretti et al., 1995; Allman et al., 
1996), in which BCL6 is critical for survival 
and proliferation. In the absence of BCL6, GC 
formation is abrogated (Dent et al., 1997; Ye 
et al., 1997). This is mainly attributed to the 
central negative regulatory effect of BCL6 on 
DNA damage response genes in GC B cells   
(Ranuncolo  et  al.,  2007).  Through  somatic 
hypermutation and DNA double-strand break 
(DSB)  events  resulting  from  class-switch  re-
combination in GCs combined with replica-
tion errors owing to a high proliferation rate, 
CORRESPONDENCE  
Markus Müschen:  
mmuschen@chla.usc.edu
Abbreviations used: ChIP,  
chromatin immunoprecipitation; 
DLBCL, diffuse large  
B cell lymphoma; DSB, double-
strand break; GC, germinal  
center; HPC, hematopoietic 
progenitor cell; KDE, -deleting 
element; QChIP, quantitative 
ChIP; RI-BPI, retro-inverso 
BCL6 peptide inhibitor; RSS, 
recombination signal sequence; 
tetO, tetracycline operator; tTA, 
tetracycline-controlled 
transactivator.
BCL6 is critical for the development  
of a diverse primary B cell repertoire
Cihangir Duy,1,2,3 J. Jessica Yu,4 Rahul Nahar,1,2 Srividya Swaminathan,1,2 
Soo-Mi Kweon,1,2 Jose M. Polo,5,6 Ester Valls,7,8 Lars Klemm,1,2  
Seyedmehdi Shojaee,1,2 Leandro Cerchietti,7,8 Wolfgang Schuh,9  
Hans-Martin Jäck,9 Christian Hurtz,1,2 Parham Ramezani-Rad,1,2  
Sebastian Herzog,10 Hassan Jumaa,10 H. Phillip Koeffler,11,12  
Ignacio Moreno de Alborán,13 Ari M. Melnick,7,8 B. Hilda Ye,4  
and Markus Müschen1,2
1Childrens Hospital Los Angeles and 2Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University  
of Southern California, Los Angeles, CA 90027
3Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany
4Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461
5Massachusetts General Hospital Cancer Center, Boston, MA 02114
6Harvard Stem Cell Institute, Boston, MA 02114
7Department of Medicine and 8Department of Pharmacology, Weill Cornell Medical College, New York, NY 10065
9Division of Molecular Immunology, Nikolaus-Fiebiger-Center for Molecular Medicine, University of Erlangen,  
91054 Erlangen, Germany
10Max-Planck Institute of Immunobiology, 79108 Freiburg, Germany
11Hematology and Oncology, Cedars Sinai Medical Center, National University of Singapore, Singapore 119077
12David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
13Centro Nacional de Biotecnología, 28049 Madrid, Spain
BCL6 protects germinal center (GC) B cells against DNA damage–induced apoptosis during 
somatic hypermutation and class-switch recombination. Although expression of BCL6 was not 
found in early IL-7–dependent B cell precursors, we report that IL-7R–Stat5 signaling 
negatively regulates BCL6. Upon productive VH-DJH gene rearrangement and expression of a  
heavy chain, however, activation of pre–B cell receptor signaling strongly induces BCL6 ex-
pression, whereas IL-7R–Stat5 signaling is attenuated. At the transition from IL-7–dependent 
to –independent stages of B cell development, BCL6 is activated, reaches expression levels 
resembling those in GC B cells, and protects pre–B cells from DNA damage–induced apoptosis 
during immunoglobulin (Ig) light chain gene recombination. In the absence of BCL6, DNA 
breaks during Ig light chain gene rearrangement lead to excessive up-regulation of Arf and 
p53. As a consequence, the pool of new bone marrow immature B cells is markedly reduced in 
size and clonal diversity. We conclude that negative regulation of Arf by BCL6 is required for 
pre–B cell self-renewal and the formation of a diverse polyclonal B cell repertoire.
© 2010 Duy et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Ig light chain rearrangement in pro–B cells (Malin et al., 2010), 
withdrawal of IL-7 from pre–B cell cultures strongly induces 
differentiation  and  Ig  light  chain  gene  rearrangement   
(Rolink et al., 1993). More recently, pharmacological inhi-
bition of v-ABL1 and BCR-ABL1 in transformed pre–B 
cells was demonstrated to have the same effect (Muljo and 
Schlissel, 2003; Klein et al., 2005). In this study, we con-
firmed that withdrawal of IL-7 from IL-7–dependent mouse 
pre–B cells and inhibition of BCR-ABL1 kinase activity in 
BCR-ABL1–transformed pre–B cells induced the transition 
from large cycling pre–B cells to small resting pre–B cells, 
with subsequent expression of  light chains on the cell sur-
face (Fig. 1 A). Inhibition of ABL1 kinase activity in trans-
formed  pre–B  cells  recapitulates  the  pre–B  to  immature   
B cell transition, including sequential initiation of DSB events 
at the V, KDE, and V gene segments (Muljo and Schlissel, 
2003; Klein et al., 2005). These experiments were performed 
using IL-7–dependent and BCR-ABL1–transformed pre–B 
cells from SLP65-deficient mice. In the presence of IL-7 or 
upon transformation by BCR-ABL1, SLP65-deficient B cell 
precursors give rise to large cycling pre–BII cells, whereas 
IL-7–dependent and BCR-ABL1–transformed SLP65 wild-
type  cells  are  arrested  at  the  pro–B/pre–BI  cell  stage  of   
development. To search for factors that are up-regulated in 
response  to  induced  Ig  light  chain  gene  rearrangement   
in pre–B cells as potential protective factors against DSB-
induced  DNA  damage  stress,  we  performed  Affymetrix 
GeneChip  analyses  of  IL-7–dependent  and  BCR-ABL1–
transformed pre–B cells before and after inhibition of IL-7 
and BCR-ABL1 kinase signaling (Fig. 1 B). IL-7 withdrawal 
and BCR-ABL1 kinase inhibition by STI571 (10 µmol/liter 
STI571 for 16 h) resulted in very similar gene expression 
changes (Fig. 1 B). Some of these gene expression changes 
can  be  attributed  to  dephosphorylation  of  STAT5-Y694 
(Walker et al., 2007), at which both the IL-7 and (BCR-) 
ABL1 signaling pathways converge (Banerjee and Rothman, 
1998; Fig. 1 C). When genes were sorted based on fold in-
crease after induced differentiation, BCL6 ranked first in the 
analysis (Fig. 1 B). Of note, the MYC protooncogene was 
among the genes on the opposite extreme of this analysis. 
Silencing of MYC and de novo expression of BCL6 upon 
inhibition of IL-7 or BCR-ABL1 signaling was confirmed   
at the protein level by Western blot analysis and correlated 
with STAT5 dephosphorylation at Y694 (Fig. 1 C). BCL6 is 
expressed at very high levels in GC B cells and serves a criti-
cal role in GC B cell survival (Dent et al., 1997; Ye et al., 
1997; Phan and Dalla-Favera, 2004). Likewise, BCL6 func-
tions as a protooncogene in DLBCL cells, where it is often 
expressed  at  very  high  levels  owing  to  the  BCL6-IGH 
translocation (t(3;14)(q27;q32); Ye et al., 1993). For these 
reasons, we studied BCL6 protein levels in pre–B cells upon 
IL-7 withdrawal as compared with GC B cells and DLBCLs 
by Western blotting (Fig. 1 D). Of note, withdrawal of IL-7 
resulted in dramatic up-regulation of BCL6 protein expres-
sion, which reached levels comparable to both DLBCLs and 
GC B cells.
GC B cells are exposed to a high level of DNA damage 
stress (Schlissel et al., 2006; Liu et al., 2008). Therefore, 
the ability of BCL6 to suppress DNA damage response and 
checkpoint genes (Shaffer et al., 2000; Shvarts et al., 2002; 
Phan and Dalla-Favera, 2004; Phan et al., 2005, Ranuncolo   
et  al.,  2008)  as  well  as  the  DNA  damage  sensor  ATR   
(Ranuncolo et al., 2007) is essential for GC B cell prolifera-
tion and survival.
Extensive DNA damage not only occurs in GCs but 
also during early B cell development in the bone marrow 
(Schlissel et al., 2006). However, previous studies focused 
on the function of BCL6 within GCs, and a role of BCL6 
in early B cell development was not examined in detail. 
Non-GC B cells, such as pre–B cells, sustain DNA damage 
owing to DNA DSBs during V(D)J recombination and 
replication errors linked to their high proliferation rate. In 
pre–B cells, DNA DSBs during V(D)J recombination first 
target one DH and JH and then multiple VH segments. This 
is followed by V-J gene rearrangement and potentially 
multiple additional rearrangements targeting the -deleting 
element (KDE) and a J-C intron element or an upstream 
V segment, before V and J gene segments are ultimately 
rearranged (Rolink et al., 1993). V(D)J recombination– 
induced DSBs activate a multifunctional expression pro-
gram (Bredemeyer et al., 2008), including proapoptotic 
pathways (Guidos et al., 1996) that can promote cell death 
unless survival pathways are concomitantly activated. It is 
currently unclear through which mechanisms pre–B cells 
are protected against extensive DNA damage stress caused 
by DSB events during V(D)J recombination at three chro-
mosomal regions (VH-DJH at 14q32; V-J, KDE-J in-
tron,  and  KDE-V  at  2p12;  and  VJ  at  22q11). 
Searching for factors that could protect pre–B cells from 
DNA damage–induced apoptosis, we established two in 
vitro systems for inducible pre–B cell differentiation and 
Ig  and  light chain gene rearrangement (Rolink et al., 
1993; Muljo and Schlissel, 2003; Klein et al., 2005). These 
cell-culture systems allow for a detailed analysis of the dif-
ferentiation of large cycling pre–BII cells (i.e., fraction C’; 
Rolink et al., 1995; Hardy and Hayakawa, 2001) to small 
resting pre–BII cells (i.e., fraction D) and ultimately to the 
immature B cell stage (i.e., fraction E). In this paper, we 
demonstrate that BCL6 function is critical for pre–B cell 
survival at the transition from IL-7–dependent to –independent 
stages of B cell development.
RESULTS
BCL6 is up-regulated during Ig light chain  
gene rearrangement
To initiate V-J and V-J gene rearrangements in pre–B 
cells and to study factors that protect pre–B cells against DSB-
mediated DNA damage stress during these recombination 
events, we used two cell-culture systems that were previ-
ously described by us and others (Rolink et al., 1993; Muljo 
and Schlissel, 2003; Klein et al., 2005). Although a recent study 
demonstrated that IL-7–Stat5 signaling prevents premature JEM VOL. 207, June 7, 2010 
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however, this ratio increased by >150-fold in small resting 
pre–BII cells (fraction D; ratio = 18). Given the role of MYC 
in cell-cycle regulation, lower mRNA levels of MYC in small 
resting compared with large cycling pre–BII cells were ex-
pected. The finding of a 20-fold up-regulation of BCL6 in 
small resting compared with large cycling pre–BII cells is novel 
albeit consistent with the cytokine context of pre–B cells at this 
differentiation stage: pre–BII cells transitioning from the large 
cycling to the small resting stage down-regulate expression of 
the IL-7 receptor (Hardy and Hayakawa, 2001; Johnson et al., 
2008). Withdrawal of IL-7 receptor signaling results in strong 
de novo expression of BCL6, as demonstrated in Fig. 1, which 
correlates with dephosphorylation of STAT5 and down-
regulation of MYC (Fig. 1 C). The inverse relationship of 
BCL6 and MYC expression is consistent with our finding that 
BCL6 is recruited and directly binds to the MYC promoter 
in BCR-ABL1–transformed pre–B cells (Fig. 2 B), suggesting 
that BCL6 functions as a transcriptional repressor of MYC. 
In addition to BCL6, expression levels of MYC are also 
negatively regulated by STI571 itself, i.e., via dephosphoryla-
tion of STAT5.
To study the functional significance of concomitant up-
regulation of BCL6 and down-regulation of MYC during 
induced pre–B cell differentiation and Ig light chain gene 
recombination, we performed gain- and loss-of-function ex-
periments (Fig. 2, C–E). In one set of experiments, IL-7– and 
BCR-ABL1–driven pre–B cells were transduced with retrovi-
ral BCL6 and MYC vectors or a GFP empty vector control. 
Upon induced pre–B cell differentiation, the pool of  light 
chain–expressing  cells  was  significantly  increased  by  BCL6 
overexpression (Fig. 2, C and D). It should be noted that over-
expression of BCL6 likely results in a competitive disadvantage 
of the BCL6-GFP–transduced cells. As shown in transformed 
pre–B cells (Fig. 2 B) and, previously, in DLBCLs (Ci et al., 
2009), BCL6 functions as a transcriptional repressor of MYC 
and may, hence, contribute to the quiescent phenotype of small 
resting pre–BII cells (BCL6high MYClow) as opposed to large 
cycling pre–BII cells (BCL6low MYChigh; Fig. 2 A).
In contrast, overexpression of MYC reduced the frequency 
of  light chain+ cells as compared with GFP empty vector 
controls in BCR-ABL1–transformed pre–B cells (treatment 
with STI571; Fig. 2 D). Also, IL-7–dependent pre–B cells 
showed a trend toward MYC-induced reduction of  light 
chain+ cells, which, however, was not statistically significant. 
Collectively, these findings suggest that BCL6 and MYC have 
opposite effects on the regulation of pre–B cell differentiation. 
To test this possibility in a genetic experiment, we combined 
retroviral overexpression of BCL6 with conditional deletion   
of MYC in IL-7–dependent pre–B cells from MYCfl/fl mice 
(Fig. 2 E). Overexpression of BCL6 alone and conditional de-
letion of MYC alone already had a statistically significant, albeit 
subtle, effect on MYCfl/fl pre–B cells in the presence of IL-7. 
Strikingly, however, combined overexpression of BCL6 with 
Cre-mediated deletion of MYC strongly promoted differentia-
tion of pre–B cells into  light chain–producing immature   
B cells, even in the presence of IL-7 (Fig. 2 E). The results 
The balance between MYC and BCL6 regulates V-J light 
chain gene recombination
To investigate whether these in vitro observations are relevant 
for mechanisms of pre–B cell differentiation in vivo, we mea-
sured the mRNA levels of BCL6 and MYC at various stages of 
B lymphopoiesis isolated from primary mouse bone marrow 
(Fig. S1). To this end, hematopoietic progenitor cells (HPCs; 
c-kit+ Sca-1+), pro–B cells (c-kit+ B220+; fractions B and C), 
large pre–BII cells (CD25+ B220low; fraction C’), and small 
pre–BII cells (fraction D), as well as immature B cells (B220low 
IgM+; fraction E), were isolated and studied by quantitative 
RT-PCR for BCL6 and MYC mRNA levels (Fig. 2 A). In 
most subsets of early B lymphopoiesis, MYC mRNA levels 
were significantly higher when compared with BCL6. In par-
ticular, the ratio of BCL6/MYC mRNA levels was very low 
in large cycling pre–BII cells (fraction C’; ratio = 0.1). Strikingly, 
Figure 1.  Regulation of BCL6 during inducible pre–B cell differen-
tiation. (A) IL-7–dependent and BCR-ABL1–transformed pre–B cells were 
induced to differentiate by withdrawal of 10 ng/ml IL-7 and ABL1 kinase 
inhibition (2 µmol/liter STI571), respectively. Cell size (FSC) and  light 
chain surface expression were monitored by flow cytometry (n = 5).  
Numbers indicate percentages. (B) To identify genes that are differentially 
regulated during induced pre–B cell differentiation, we studied pre–B cells 
stimulated to differentiate in a microarray analysis. Genes were sorted 
based on the ratio of gene expression values observed upon withdrawal 
of IL-7 from IL-7–dependent pre–B cells. (C) Likewise, protein lysates  
from pre–B cells in the presence or absence of induced differentiation  
(treatment with 10 µmol/liter STI571 or withdrawal of IL-7 for 24 h) were 
analyzed by Western blotting using antibodies against STAT5, phosphory-
lated STAT5 at Y694, BCL6 (clone N3), MYC, and an ACTB antibody as 
loading control (n = 6). The asterisk denotes a nonspecific band that is 
consistently observed with the N3 BCL6 antibody. Of note, BCR-ABL1 
kinase signaling results in stronger STAT5 tyrosine phosphorylation at 
Y694 and detection of two phosphoproteins compared with IL-7–dependent 
STAT5 phosphorylation, where only one band is detected (see D). (D) To 
directly compare BCL6 protein expression levels in pre–B cells upon IL-7 
withdrawal and DLBCL cells and tonsillar GC B cells, Western blot analyses 
were repeated with cell lysates from these cell populations (cell lysates 
from three IL-7 withdrawal experiments). FSC, forward scatter.1212 BCL6 promotes pre–B cell self-renewal | Duy et al.
vector. In contrast, pre–B cells transduced with the 
constitutively  active  STAT5  mutant  maintained 
some  STAT5  phosphorylation  even  after  IL-7 
withdrawal, and up-regulation of BCL6 was greatly 
attenuated (Fig. 3 A). This finding demonstrates 
that active STAT5 functions as a negative regulator 
downstream of the IL-7 receptor. To verify that withdrawal 
of IL-7 not only results in BCL6 up-regulation in long-term 
IL-7–dependent pre–B cell cultures, we used a neutralizing 
anti–IL-7 antibody to inactivate IL-7 receptor signaling in 
freshly ex vivo–isolated (B220+ MACS) bone marrow B 
cell precursors (Fig. 3 B). Although both populations strongly 
up-regulated BCL6 in response to anti–IL-7 antibody treat-
ment, the antibody had a stronger effect in long-term pre–B 
cell cultures than in freshly isolated ex vivo B220+ bone 
marrow cells. This difference likely reflects a higher de-
gree of enrichment for IL-7–responsive cells in long-term 
IL-7 pre–B cell cultures than in B220+ bone marrow cells 
(Fig. 3 B).
Although these findings establish that IL-7R–STAT5 
signaling negatively regulates BCL6 expression in pre–BII 
cells, it is not clear how BCL6 expression can be activated 
in these cells. To address this question, we used a model in 
which inducible de novo synthesis of the pre–B cell receptor 
recapitulates the transition of pro–B cells (fractions B and C) 
into large cycling pre–BII cells (after 2 d; fraction C’) and then 
demonstrate that the balance between BCL6 and MYC deter-
mines the large cycling (fraction C’) versus small resting (fraction 
D) phenotypes of pre–BII cells. We conclude that the geneti-
cally induced inversion of the BCL6/MYC ratio in pre–BII cells 
in this experiment is required and sufficient to recapitulate the 
effect of IL-7 withdrawal on pre–B cell differentiation.
Pre–B cell receptor activation induces expression of BCL6 
via down-regulation of IL-7 responsiveness
In Fig. 1 C, we observed that up-regulation of BCL6 corre-
lated with dephosphorylation of STAT5 Y694 upon with-
drawal of IL-7 receptor signaling. This finding suggests that 
active STAT5 (phosphorylated at Y694) functions as a nega-
tive regulator of BCL6 expression downstream of the IL-7   
receptor. To mechanistically address this possibility, IL-7–
dependent pre–B cells were transduced with a retroviral vec-
tor encoding a constitutively active STAT5 mutant (Onishi 
et al., 1998) or an empty vector control. Withdrawal of IL-7 re-
sulted in both dephosphorylation of STAT5 and up-regulation 
of BCL6 in pre–B cells that were transduced with an empty 
Figure 2.  The balance between MYC and BCL6 regu-
lates V-J light chain gene recombination. (A) HPCs, 
pro–B cells (fractions B and C), large cycling pre–BII cells 
(fraction C’), small resting pre–BII cells (fraction D), and  
immature B cells (fraction E) were sorted from normal mouse 
bone marrow (n = 3) and subjected to quantitative RT-PCR 
to measure mRNA levels of BCL6 and MYC relative to Hprt. 
Mean values ± SD of three experiments are given. Numbers 
in the bar chart denote the ratios of BCL6 versus MYC mRNA 
levels. (B) Recruitment of BCL6 to the MYC promoter was 
identified by ChIP-on-chip analysis and confirmed by single 
locus QChIP analysis. ChIP-on-chip analysis was performed 
for three BCR-ABL1–transformed pre–B cell lines (each two 
replicates) under control conditions or after treatment with 
10 µmol/liter STI571 for 24 h. Two replicate experiments for 
one BCR-ABL1–transformed pre–B ALL cell line are shown.  
(C and D) IL-7–dependent (C) and BCR-ABL1–transformed 
(D) pre–B cells were induced to differentiate by IL-7 with-
drawal or inhibition of BCR-ABL1 kinase activity. To test the 
function of MYC and BCL6 during induced pre–B cell differ-
entiation, pre–B cells were transduced with retroviral vectors 
encoding BCL6-IRES-GFP, MYC-IRES-GFP, or an IRES-GFP 
empty vector control. Percentages of  light chain+ GFP+ 
cells are indicated (mean values of three experiments ± SD). 
(E) IL-7–dependent bone marrow pre–B cells from MYCfl/fl 
and MYCfl/fl × mx-Cre mice were transduced with retroviral 
vectors encoding BCL6-IRES-GFP or an IRES-GFP (empty 
vector control) and cultured in the presence of 10 ng/ml IL-7. 
2,500 U/ml IFN- was added to all cultures to induce expres-
sion of Cre and MYC deletion in Mx-Cre × MYCfl/fl but not 
MYCfl/fl pre–B cells (mean values ± SD; n = 3).JEM VOL. 207, June 7, 2010 
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in BCL6/ compared with wild-type bone marrow, the   
frequency of IgM+ and  light chain+ immature B cells was 
significantly diminished (Fig. 4, A and B; statistical analysis 
in Table S1). Compared with wild-type cells, c-kit+ B220+ 
(fraction B) and CD43+ B220+ (fraction C) pro–B cell popu-
lations were slightly expanded in BCL6/ bone marrow. In 
agreement with previous studies (Dent et al., 1997; Ye et al., 
1997),  light chain–expressing immature B cells (fraction E) 
were detected in BCL6/ bone marrow, but their frequency 
was approximately fivefold lower than in wild-type mice   
(P = 0.03; Table S1).
To study the clonal composition of IgM+ + bone mar-
row immature B cells (fraction E) that developed in the ab-
sence of BCL6, we sorted 8,000 B220+ IgD + bone marrow 
cells from both BCL6/ and BCL6+/+ bone marrow and 
analyzed them by spectratype analysis. Although wild-type 
B220+ IgD + bone marrow immature B cells exhibit a 
small resting pre–BII cells (after 4 d; fraction D): pro–B cells 
from RAG2/ tetracycline-controlled transactivator (tTA)/ 
chain–transgenic mice (Hess et al., 2001) are unable to express 
an endogenous  chain because of a lack of RAG2-dependent 
V(D)J recombination. Although these pro–B cells carry their 
endogenous Ig heavy chain loci in germline configuration, 
they also harbor a functionally prerearranged  chain under 
the control of tetracycline operator (tetO) sequences. In addi-
tion, RAG2/ tTA/ chain–transgenic mice express a tTA 
under control of endogenous  chain regulatory elements. We 
verified induction of  chain expression in RAG2/ tTA/ 
chain–transgenic IL-7–dependent pro–B cell cultures by flow 
cytometry (Fig. 3 C). In agreement with previously published 
data (Schuh et al., 2008), we observed that induction of  
chain expression in RAG2/ tTA/ chain–transgenic pro–B 
cells results in down-regulation of CD43 and up-regulation of 
CD25, which is consistent with a pro–B to pre–B cell transi-
tion (Hardy and Hayakawa, 2001). 2 d after induction of  
chain expression, the cells had assumed a large cycling pheno-
type (fraction C’), followed by cell-cycle exit and reduction of 
cell size (small resting pre–BII cell; fraction D; Trageser et al., 
2009). A Western blot analysis performed with cells that were 
harvested after 4 d of  chain induction showed strong up-
regulation of BCL6 together with near complete dephosphor-
ylation of STAT5 (Fig. 3 C). These findings demonstrate that 
the transition from IL-7R–STAT5 signaling in large cycling 
pre–BII cells (fraction C’) to BCL6 expression in small cycling 
pre–BII cells (fraction D) is initiated by the pre–B cell receptor. 
The finding of pre–B cell receptor–mediated down-regulation 
of IL-7R–STAT5 signaling is consistent with a recent study, 
which demonstrated that IL-7R–STAT5 signaling prevents 
premature Ig light chain gene recombination in pro–B cells 
(Malin et al., 2010). Experiments to delineate the details of 
pre–B cell receptor–dependent activation of BCL6 are cur-
rently under way. In this context it is noteworthy that recon-
stitution of the pre–B cell receptor linker molecule SLP65 in 
SLP65/ pre–B cells results in down-regulation of IL-7R 
surface expression (Fig. 3 D) and reduced IL-7 responsiveness 
(Schebesta et al., 2002). In addition, a recent study showed 
that pre–B cell receptor–dependent activation of SLP65 leads 
to dephosphorylation of STAT5 via inhibition of JAK3   
(Nakayama et al., 2009). We conclude that BCL6 activation in 
B cell precursors is naturally confined to the pre–B cell com-
partment and is induced after de novo synthesis of the pre–B 
cell receptor based on productively rearranged VH-DJH gene 
segments. We propose that down-regulation of IL-7 respon-
siveness represents an important aspect through which pre–B 
cell receptor signaling induces expression of BCL6 in small 
resting pre–BII cells.
BCL6 is required for normal polyclonal B lymphopoiesis
To investigate the physiological relevance of BCL6 during 
early B cell development, we performed a detailed flow cy-
tometry analysis of bone marrow samples from age-matched 
BCL6/ and BCL6+/+ mice (n = 4). Although the total 
number of B220+ B cell lineage cells was only slightly reduced 
Figure 3.  Pre–B cell receptor activation induces expression of BCL6 
via down-regulation of IL-7 responsiveness. IL-7–dependent pre–B cells 
were transduced with a retroviral vector encoding a constitutively active 
STAT5 mutant (STAT5-CA-GFP; Onishi et al., 1998) or an empty vector control 
(GFP). (A) GFP-expressing transduced cells were sorted, subjected to IL-7 
withdrawal, and analyzed by Western blotting for expression of BCL6 and 
tyrosine phosphorylation of STAT5 using -actin as a loading control (n = 3). 
(B) Mouse B cell precursors were isolated by B220+ MACS from freshly har-
vested bone marrow cells. Freshly isolated bone marrow B cell precursors 
and IL-7–dependent pre–B cell cultures were treated with 10 µg/ml of a 
neutralizing anti–IL-7 antibody overnight and were subjected to Western 
blot analysis (three experiments were performed). (C) Bone marrow B cell 
precursors from RAG2/ tTA/ chain–transgenic mice are unable to express 
an endogenous  chain but carry a functionally prerearranged  chain  
under control of tetO sequences (Hess et al., 2001). These mice express a tTA 
under control of endogenous  chain regulatory elements, and withdrawal 
of tetracycline results in activation of  chain expression (routinely per-
formed quality control). The effect of tetracycline-inducible activation of  
chain expression on BCL6 expression and STAT5 tyrosine phosphorylation 
was determined by Western blotting (n = 3; right). (D) IL-7–dependent pre–B 
cells lacking the pre–B cell receptor–related linker molecule SLP65 were 
transduced with retroviral expression vectors encoding either SLP65-GFP or 
GFP alone. Surface expression levels of IL-7R chain were measured by flow 
cytometry (the experiment was performed twice). The histogram shows the 
IL-7R levels in transduced GFP+ (green) and untransduced (gray) cells.1214 BCL6 promotes pre–B cell self-renewal | Duy et al.
FN652777, and FN652778; Table S2). In addition, clonal ex-
pansions within the bone marrow immature B cell and mature 
splenic B cell pool in BCL6/ mice carried the same VH-DJH 
junction and, hence, share the same clonal origin (Fig. 5 B). 
Two large clones were amplified from the bone marrow and 
spleen of BCL6/ mouse #I, and one clonal expansion in the 
bone marrow of BCL6/ mouse #II was also recovered from 
the spleen. These findings further illustrate that even though 
the size of a peripheral B cell pool may be normal in BCL6/ 
mice (Dent et al., 1997; Ye et al., 1997), the primary B cell 
repertoire in BCL6/ mice is restricted to a small number of 
dominant clones.
A more detailed analysis of VH-DJH junctions revealed that 
many other seemingly unique VH-DJH rearrangements ampli-
fied from BCL6/ mature splenic B cells in fact harbor the 
same D-JH junction (gray shading in Table S2) but have rear-
ranged different VH gene segments. These clones are derived 
from one parental bone marrow immature B cell clone but 
subsequently diversified in the spleen by VH replacement, i.e., 
by substitution of the initially rearranged VH segment by a VH 
segment located upstream. VH replacement (Reth et al., 1986) 
involves the recombination signal sequence (RSS) of a nonre-
arranged VH gene and a cryptic RSS (i.e., an isolated heptamer) 
within the preexisting VHDJH joint. The cryptic RSS (high-
lighted in red in Fig. 5 B) is located at the 3 end of the major-
ity of VH gene segments in mice and humans (Radic and 
Zouali, 1996). The spectratyping profiles shown in Fig. 5 A 
seem to suggest that the extreme oligoclonality observed 
among BCL6/ bone marrow immature B cells is alleviated 
broad polyclonal repertoire, the profile of BCL6/ bone 
marrow immature B cells was oligoclonal (Fig. 4 C). These 
findings are based on sorted immature B cells from four pairs 
of BCL6+/+ and BCL6/ mice, and suggest that BCL6 is re-
quired for normal polyclonal B cell production. To verify the 
clonal  composition  of  the  primary  B  cell  repertoire  in 
BCL6+/+ and BCL6/ mice, we performed a detailed se-
quence analysis for two pairs of mice where immature B cells 
from bone marrow and mature B cells from spleens were 
available for cell sorting from the same animals (Fig. 5). Inter-
estingly, in two BCL6/ mice, spectratyping identified 
clonal expansions with the same peak size (i.e., the same 
length of the VH-DJH junction; Fig. 5 A) that were amplified 
from both the bone marrow and the spleen of these mice. 
This finding raises the question of whether the clonal expan-
sions  among  bone  marrow  immature  B  cells  and  mature 
splenic B cells in BCL6/ mice are derived from the same 
dominant clone.
To test this possibility, we performed a comprehensive se-
quence analysis of VH-DJH junctions in bone marrow imma-
ture B cells and splenic mature B cells from BCL6+/+ and 
BCL6/ mice, respectively (Fig. 5 B and Table S2). Consistent 
with the finding of a restricted B cell repertoire in BCL6/ 
mice (Fig. 4 C and Fig. 5 A), we amplified multiple clonally 
related sequences from BCL6/ but not from BCL6+/+ mice 
(available from GenBank/EMBL/DDBJ under accession nos. 
FN652762, FN652763, FN652764, FN652765, FN652766, 
FN652767, FN652768, FN652769, FN652770, FN652771, 
FN652772, FN652773, FN652774, FN652775, FN652776, 
Figure 4.  Normal polyclonal B lymphopoiesis requires BCL6 survival signaling in late pre–B cells. Bone marrow mononuclear cells from BCL6+/+ and 
BCL6/ mice were analyzed by flow cytometry using the indicated antibody combinations (numbers indicated percentages). (A) Bone marrow cells were ana-
lyzed using a FSC/SSC gate together with propidium iodide exclusion (viable lymphocytes). (B) Cells were analyzed using a B220+ gate. Four mice were studied 
in each group, and a detailed statistical analysis including absolute cell numbers is presented in Table S1. (C) To examine the clonal composition of + imma-
ture B cells (fraction E), B220+ IgD + cells were sorted and analyzed by Ig spectratyping. Spectratyping analysis separates Ig gene rearrangements based on 
the length of their VH-DJH junction, and the height (fluorescence intensity) of each size peak indicates its relative representation within the B cell population 
analyzed. Individual size peaks are typically separated by 3 bp, reflecting the reading frame in functional VH-DJH gene rearrangements. In total, four pairs of 
BCL6+/+ and BCL6/ bone marrow–derived immature B cell samples were analyzed by spectratyping. FSC, forward scatter; SSC, side scatter.JEM VOL. 207, June 7, 2010 
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the bone marrow HPCs die, whereas B cell lineage cells 
vigorously proliferate (Fig. S2 A). We verified that the IL-7– 
dependent and BCR-ABL1–transformed cells used are indeed 
pre–B cells based on positive intracellular staining for µ chain 
and CD25 expression (Fig. S2 B). IL-7–dependent pre–B cell 
proliferation was robustly induced in bone marrow samples 
from BCL6+/+ mice, and pre–B cell cultures can be expanded 
for up to 2 mo until pre–B cell cultures become senescent 
(unpublished data). In striking contrast, BCL6/ pre–B cells 
consistently failed to propagate ex vivo even in the presence of 
10 ng/ml IL-7. Although wild-type pre–B cells start to vigor-
ously expand on day 3, no viable B cell precursors can be de-
tected in IL-7 cultures from BCL6/ bone marrow (Fig. S2 A).   
Because BCL6/ pre–B cells failed to differentiate and died 
upon IL-7 withdrawal even after short-term culture (Fig. S2 A), 
we studied differentiation in BCR-ABL1–transformed pre–
B cells, as described in Fig. 1 A. Compared with wild-type 
pre–B cells, transformation of fresh BCL6/ pre–B cells was 
significantly delayed, cells proliferated at a reduced rate, and in 
some instances transformation failed entirely (unpublished data). 
However, we found after successful BCR-ABL1 transforma-
tion of BCL6+/+ and BCL6/ cells that inhibition of BCR-
ABL1 kinase activity induced differentiation into + immature 
to some degree within the pool of BCL6/ mature splenic   
B cells. It is likely, however, that many of these additional 
clones have diversified by VH gene replacement, share the same 
D-JH junction, and are, hence, derived from a very small num-
ber of immature B cells that have left the bone marrow. We 
conclude that the ability of small resting pre–BII cells to up-
regulate BCL6 is critical for the development of a diverse pri-
mary B cell repertoire.
BCL6 is required for self-renewal signaling  
at the pre–B cell stage
Previous work demonstrated that a fraction of BCL6/ mice 
suffers from chronic inflammation (Dent et al., 1997; Ye et al., 
1997), which may affect the composition of the B cell progen-
itor populations within the bone marrow. In the animals we 
analyzed in this study, no signs of inflammatory disease were 
noted. In addition, we tested the ability of BCL6/ pre–B 
cells to differentiate under cell-culture conditions, which 
excludes  potential  side  effects  from  inflammation  (Fig.  S2).   
We first incubated bone marrow samples from BCL6+/+ and 
BCL6/ mice in the presence of 10 ng/ml IL-7, which se-
lectively induces proliferation of bone marrow pre–B cells. In 
the presence of high IL-7 concentrations, the majority of 
Figure 5.  BCL6 is required for the development of a diverse primary B cell repertoire. (A) For two pairs of BCL6+/+ and BCL6/ mice (I and II), in 
addition to bone marrow samples spleen tissue was also available. Immature B cells (fraction E) from bone marrow and mature B cells from spleens (frac-
tion F) were sorted and subjected to spectratyping analysis to study length diversity of VH-DJH junctions. In two BCL6/ mice, clonal expansions were 
identified that occurred both in the bone marrow and in the spleen with the same peak size, i.e., the same length of the VH-DJH junction. Two such clonal 
expansions were found in BCL6/ mouse I (I.1 and I.2) and one expansion was found in BCL6/ mouse II (II.1). (B) To test whether these expansions with 
the same length of the VH-DJH junction indeed belong to one clone, we performed a detailed sequence analysis of these VH-DJH junctions. Alignments of 
VH, D, and JH gene segments are shown as well as N/P nucleotides in the junctional regions. Internal heptamers are highlighted in red, and sites at which 
the junctional homology with the parental VH-DJH rearrangement ends are indicated by arrows.1216 BCL6 promotes pre–B cell self-renewal | Duy et al.
STI571  treatment  induced  increased  V(D)J  recombinase 
activity and increased cell death both in BCL6+/+ and BCL6/ 
cells. However, the outcome of STI571-induced V(D)J re-
combination activity differs between BCL6+/+ and BCL6/ 
cells: in BCL6+/+ cells, STI571-induced recombinase activ-
ity results in higher output of + cells. In BCL6/ cells, 
STI571-induced recombination results in increased cell death 
(Fig. S3, B and C).
These findings suggest that DNA DSB events during V-
J  gene  rearrangement  are  directly  linked  to  apoptosis  in 
BCL6/ pre–B cells. To test this possibility, we induced dif-
ferentiation in IL-7–dependent B cell precursors carrying a 
homozygous deletion of the RAG1 gene, which is required 
for V(D)J recombination. Upon withdrawal of IL-7, RAG1/ 
B cell precursors undergo phenotypic changes consistent with 
differentiation, as in wild-type pre–B cells (Fig. S4), but fail to 
introduce DNA DSBs at V- and J genes. To test the role of 
BCL6 in this system, we used a peptidomimetic inhibitor   
of  BCL6  (retro-inverso  BCL6  peptide  inhibitor  [RI-BPI]; 
Cerchietti et al., 2009), which was recently developed for the 
treatment of GC-derived B cell lymphoma (Polo et al., 2004). 
Withdrawal of IL-7 had a similar effect in both RAG1/ and 
wild-type B cell precursors, and induced phenotypic differen-
tiation (down-regulation of CD43 and up-regulation of CD25) 
in most cells but apoptosis only in a small fraction (Fig. S4). 
Concomitant withdrawal of IL-7 and peptidomimetic inhibi-
tion of BCL6 increased the fraction of apoptotic cells in both 
Rag1/ and wild-type B cell precursors. Although >50% of 
RAG1/ B cell precursors survived simultaneous inhibition 
of IL-7 and BCL6 signaling, almost all cells in which DNA 
DSBs could be introduced during induced V-J gene rear-
rangement underwent apoptosis (annexin V+; Fig. S4). Like-
wise, concomitant inhibition of IL-7 and BCL6 compromised 
the survival of differentiating (CD25+ CD43) subclones, un-
less introduction of DNA DSBs during V(D)J recombinase 
activity was prevented in RAG1/ B cell precursors (Fig. S4). 
These striking differences indicate that BCL6 function in dif-
ferentiating pre–B cells is mainly needed to counteract the 
apoptotic DNA damage response induced by DNA DSBs 
during Ig light chain gene rearrangement.
BCL6 is required for transcriptional repression of DNA 
damage response genes during Ig light chain recombination
To elucidate the mechanism of BCL6-mediated pre–B cell sur-
vival signaling, we next investigated the gene expression pattern   
in BCL6/ and BCL6+/+ pre–B cells (Fig. 6 A). Importantly, 
well-known cell-cycle checkpoint regulators (CDKN1A/
p21, CDKN1B/p27, and CDKN2A/Arf) and inducers of cel-
lular senescence (CDKN2A/Arf) are among the targets of 
BCL6-mediated transcriptional repression (Fig. 6, A and B),   
which directly supports a central role of BCL6 in pre–B 
cell self-renewal signaling and protection against DNA damage– 
induced apoptosis (e.g., during V-J gene rearrangement). 
These differences could be confirmed by quantitative RT-PCR 
for ARF, p21, and p27 (highlighted in Fig. 6, A and B). In 
the absence of BCL6, p21, p27, and ARF showed excessive 
B cells in 3% of wild-type pre–B cells within 3 d, whereas 
no significant differentiation but markedly enhanced cell death 
was observed in BCL6/ pre–B cells (Fig. S3 A).
BCL6 protects pre–B cells against apoptosis  
during V-J recombination
We next compared V(D)J recombinase activity in BCL6/ 
and wild-type pre–B cells before and after induced differentia-
tion. To this end, we transduced BCR-ABL1–transformed 
pre–B cells with a retrovirus carrying an inverted GFP cassette 
flanked by RSS as in V and J gene segments. Upon inver-
sion-mediated recombination of the RSS-flanked GFP, the 
GFP cassette will be in the correct orientation and expressed 
from the retroviral long terminal repeat (Fig. S3 B). Equal 
numbers of BCL6/ and wild-type pre–B cells were trans-
duced and subjected to selection for antibiotic resistance en-
coded by the RSS-GFP reporter construct (Wossning et al., 
2006). We detected spontaneous V(D)J recombinase activity 
in  both  untreated  BCR-ABL1–transformed  BCL6+/+  and 
BCL6/ pre–B cells, and the frequency of cells with recom-
binase activity was higher in the wild-type cells (20% 
compared with 2%; P < 0.01; Fig. S3 B). When BCR-
ABL1–transformed pre–B cells were stimulated to differenti-
ate by BCR-ABL1 kinase inhibition, the frequency of cells 
undergoing RSS-dependent recombination events increased 
in both BCL6/ and wild-type pre–B cells. RSS-targeted re-
combination events were followed by de novo expression of  
light chains in wild-type pre–B cells. Strikingly, however, the 
frequency of + cells did not significantly increase in STI571-
treated BCL6/ pre–B cells despite recombination activity in 
these cells (Fig. S3 B). This difference between BCL6/ and 
BCL6+/+ pre–B cells could indicate that BCL6 is required for 
targeting of the V(D)J recombinase to the Ig  light chain locus. 
Alternatively, BCL6 may have a role in the intracellular pro-
cessing of  light chains and their pairing with Ig heavy chains. 
Finally, V-J rearranging pre–B cells might undergo apopto-
sis in the absence of BCL6 before  light chains can be ex-
pressed on the cell surface. To directly test the latter hypothesis, 
we measured the percentage of apoptotic cells (annexin V+) in 
BCL6+/+ and BCL6/ pre–B cells with (RSS-GFP+) and 
without (RSS-GFP) indication of V(D)J recombinase activ-
ity (Fig. S3 C). If lack of  light chain expression on BCL6/ 
pre–B cells was indeed linked to apoptosis during V-J rear-
rangement, one would expect that RSS-GFP+ cells were pref-
erentially apoptotic in the case of BCL6/ but not BCL6+/+ 
cells. Induction of differentiation by STI571 treatment resulted 
in a strong increase of V(D)J recombinase activity, both in 
BCL6+/+ and BCL6/ pre–B cells (Fig. S3 C). Among BCL6+/+ 
cells, only a minority of V(D)J recombining pre–B cells (RSS-
GFP+) was apoptotic in the presence (24% of all RSS-GFP+ 
cells) or absence (13% of RSS-GFP+ cells) of STI571-treatment. 
In contrast, however, no enrichment of viable cells was ob-
served among BCL6/ pre–B cells that underwent V(D)J 
recombination: approximately one half of BCL6/ V(D)J re-
combining pre–B cells (RSS-GFP+) was apoptotic in the pres-
ence and absence of STI571 treatment (Fig. S3 C). In summary, JEM VOL. 207, June 7, 2010 
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p14ARF showed 0.74 ± 0.2% of input for BCL6 compared 
with 0.03 ± 0.01% of input using a -actin antibody as 
negative control (n = 3; P = 0.02).
BCL6 promotes pre–B cell survival by negative  
regulation of ARF
Consistent with the identification of CDKN2A (ARF) as a 
direct transcriptional target of BCL6, we found that protein 
levels of both Arf and its downstream effector p53 are exces-
sively increased in BCR-ABL1–transformed BCL6/ pre–B 
cells (Fig. 6 D). To investigate the functional significance of 
transcriptional repression of ARF by BCL6, we studied the role 
of ARF in a genetic loss-of-function model. We tested whether 
pre–B cell apoptosis resulting from inhibition of BCL6 is in part 
mediated by excessive activation of Arf. To this end, we induced 
differentiation in wild-type and Arf-deficient BCR-ABL1 pre–
B cells by treatment with STI571 in the presence or absence of 
concomitant BCL6 inhibition (RI-BPI; Fig. 6 E). Induced dif-
ferentiation (STI571) or inhibition of BCL6 (RI-BPI) alone had 
little effect on the viability of both wild-type and ARF/ pre–
B cells. Simultaneous induction of differentiation and inhibition 
of BCL6, however, induced apoptosis in the vast majority of 
up-regulation after STI571 treatment, and Arf mRNA levels 
were increased in BCL6-deficient pre–B cells even in the ab-
sence of induced differentiation. Although p21 and p27 were 
previously identified as target genes of BCL6-mediated tran-
scriptional repression (Shaffer et al., 2000; Phan and Dalla- 
Favera, 2004; Phan et al., 2005), transcriptional silencing of ARF 
by BCL6 represents a novel finding. To determine whether 
BCL6 could bind to the ARF locus, we performed BCL6 
chromatin immunoprecipitation (ChIP)–on-chip using a 
genomic microarray tiling across the entire CDKN2A locus 
(Fig. 6 C) in the human B cell lymphoma cell line OCI-Ly1. 
The CDKN2A gene contains two start exons (1 and 1) that 
give rise to two alternative transcripts, p14ARF and p16INK4A. 
The ChIP-on-chip result demonstrated that BCL6 was strongly 
bound to sequences proximal to the p14ARF transcriptional start   
site (Fig. 6 C). ChIP-on-chip also showed that BCL6 also bound,   
albeit weakly, to sequences related to p16INK4a (Fig. 6 C). BCL6 
binding to the p14ARF promoter was confirmed by perform-
ing additional quantitative ChIP (QChIP) assays using primers 
to amplify this site. BCL6 single-locus QChIP for CDKN2A/
Figure 6.  BCL6 promotes pre–B cell survival by negative 
regulation of ARF. (A) BCR-ABL1–transformed BCL6+/+ and BCL6/ 
pre–B cells were induced to differentiate (10 µmol/liter STI571) and 
studied by microarray analysis. Genes were sorted based on the ratio 
of gene expression values in STI571-treated BCL6+/+ compared with 
BCL6/ pre–B cells. (B) Differences in mRNA levels of checkpoint 
genes (ARF, p21, and p27) were verified by quantitative RT-PCR using 
HPRT as a reference (mean values ± SD; n = 3). (C) Recruitment of 
BCL6 to the genomic region of the CDKN2A locus (ARF) was verified 
by ChIP-on-chip analysis and confirmed by single locus QChIP analy-
sis (n = 3). BCL6–DNA complexes were immunoprecipitated using 
an anti-BCL6 polyclonal antibody. ChIP products and their respective 
input genomic fragments were amplified by ligation-mediated PCR. 
QChIP was performed again at this stage for selected positive con-
trol loci to verify that the enrichment ratios were retained (not de-
picted). The genomic products of two biological ChIP replicates were 
labeled with Cy5 (for ChIP products) and Cy3 (for input) and co-
hybridized on genomic tiling arrays including the genomic region of 
the CDKN2A locus (Chr9:21,950629–22,003329). After hybridization, 
the relative enrichment for each probe was calculated as the signal 
ratio of ChIP to input. Peaks of enrichment for BCL6 relative to input 
were uploaded as custom tracks into the University of California, 
Santa Cruz genome browser and graphically represented as histo-
grams. Peaks involving five or more oligonucleotide probes above 
threshold (2.5-fold SD above average enrichment) were considered 
positive. (D) To determine whether recruitment of BCL6 to the Arf 
(CDKN2A) promoter affects expression levels of proteins in the Arf–
p53 pathway, BCR-ABL1–transformed BCL6+/+ and BCL6/ pre–B 
cells were analyzed by Western blotting. (E) BCR-ABL1–transformed 
pre–B cells from ARF+/+ and ARF/ mice were induced to differenti-
ate (+STI571) or cultured under control conditions in the presence or 
absence of 5 µmol/liter of a peptidomimetic BCL6 inhibitor (RI-BPI; 
Cerchietti et al., 2009). Cell size (FSC) and viability (propidium iodide 
uptake) were measured by flow cytometry after 1 and 3 d (n = 3). 
Percentages of viable cells are indicated for each condition. FSC, 
forward scatter; PI, propidium iodide.1218 BCL6 promotes pre–B cell self-renewal | Duy et al.
excessive activation of DNA damage response and check-
point genes (ARF, p53, p21, and p27; Fig. 6), and only a few 
small resting pre–BII cells survive the transition from IL-7–
dependent to –independent B cell development. Based on 
the timing of its expression and its ability to curb an excessive 
DNA damage response during light chain gene recombina-
tion, BCL6 plays a central role in the generation of a diverse 
primary B cell repertoire.
MATERIALS AND METHODS
BCL6/, MYCfl/fl × mx-Cre, ARF (CDKN2A)/, SLP65/, and 
RAG1/ mice. Bone marrow from BCL6/ mice (a gift from R. Dalla-
Favera, Columbia University, New York, NY; Ye et al., 1997) was har-
vested, and bone marrow cells were cultured either in the presence of 10 ng 
IL-7/ml in RetroNectin-coated (Takara Bio Inc.) Petri dishes or retrovirally 
transformed by BCR-ABL1 as described in In vitro pre–B cell differentia-
tion assays. Likewise, bone marrow B cell precursors from MYCfl/fl × mx-Cre 
and MYCfl/fl mice (Baena et al., 2005) were cultured in the presence of 
10 ng/ml IL-7 on RetroNectin. Deletion of Myc was induced by IFN-–
mediated (2,500 U/ml; PBL Interferon Source) induction of mx-Cre activa-
tion. SLP65/ pre–B cells were extracted from bone marrow of SLP65/ 
mice (Jumaa et al., 1999). RAG1/ and CDKN2A/ mice were pur-
chased from the Jackson Laboratory. All pre–B cells derived from bone marrow 
of mice were maintained in IMDM (Invitrogen) with GlutaMAX contain-
ing 20% fetal bovine serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, 
50 µM 2-mercaptoethanol, and 10 ng/ml of recombinant mouse IL-7   
(PeproTech) at 37°C in a humidified incubator with 5% CO2. All mouse 
experiments were subject to approval by the Children’s Hospital Los Angeles 
Institutional Animal Care and Use Committee.
RAG2/  tTA/  chain–transgenic  mice.  RAG2/  tTA/  chain–
transgenic mice (Hess et al., 2001) are unable to express an endogenous  
chain because of a lack of RAG2-dependent V(D)J recombination but carry 
a functionally prerearranged  chain under control of tetO sequences in the 
germline. In addition, RAG2/ tTA/ chain–transgenic mice express a 
tTA under control of endogenous  chain regulatory elements.
In vitro pre–B cell differentiation assays. Polyclonal pre–B cells were 
either propagated in the presence of 10 ng/ml IL-7 or transformed using a 
murine stem cell virus (MSCV) retrovirus encoding BCR-ABL1-IRES-
GFP (Pear et al., 1998) or BCR-ABL1-IRES-Neo. Induction of differentia-
tion was either induced by withdrawal of IL-7 (Rolink et al., 1993) or 
inhibition of BCR-ABL1 kinase activity using 2 µmol/liter STI571. STI571 
(imatinib) was provided by Novartis. After 3 d of IL-7 withdrawal or STI571 
treatment, successful induction of differentiation was verified by flow cy-
tometry analysis of  light chain surface expression.
Neutralization of IL-7 activity in ex vivo–isolated bone marrow   
B cell precursors. Bone marrow was isolated from C57B/6J mice, and   
B cell lineage cells were isolated using B220+ MACS beads (Miltenyi Bio-
tec). Viability and purity of isolated B cell lineage cells was verified by flow 
cytometry. B220+ cells were incubated overnight on OP9 stroma cells with 
1 ng/ml IL-7 in the presence or absence of 10 µg/ml of a neutralizing 
anti–mouse IL-7 antibody (goat polyclonal IgG; R&D Systems). After 12 h, 
cells were harvested and protein lysates were analyzed by Western blotting 
for expression of BCL6 using -actin as loading control.
RI-BPI. Homodimerization of the BCL6 BTB domain forms a lateral 
groove motif, which is required to recruit the silencing mediator of reti-
noid and thyroid receptors (SMRT) and the nuclear receptor corepressor 
(N-CoR) to form a BCL6 repression complex (Ahmad et al., 2003). Amino 
acid side chains protruding into this groove make extensive contact with an 
18-residue BCL6 binding domain (BBD) peptide that is conserved between 
SMRT and N-CoR. The BCL6 lateral groove residues that contact N-CoR 
and SMRT are unique and are not present in other BTB domain proteins.   
wild-type pre–B cells (viability < 1%). In contrast, a significant 
portion of ARF/ pre–B cells survived concomitant induction 
of differentiation and inhibition of BCL6 (viability > 40%; 
Fig. 6 E). We conclude that de novo expression of BCL6 at the 
transition from IL-7–dependent to –independent stages of B cell 
development is required to promote pre–B cell survival by nega-
tive regulation of Arf.
DISCUSSION
Based on our observations, we propose the following scenario of 
BCL6-mediated survival signaling at the transition from   
IL-7–dependent to –independent stages of B cell development 
(Fig. S5). Large cycling pre–BII cells express high levels of the 
IL-7 receptor (Fig. 3 D; Hardy and Hayakawa, 2001; Johnson 
et al., 2008), ligation of which induces tyrosine phosphorylation 
of JAK1, JAK3, and STAT5 (Palmer et al., 2008). STAT5 phos-
phorylation at Y694 leads to transcriptional suppression of BCL6 
(Fig. 1 C and Fig. 3 A; Walker et al., 2007) and transcriptional 
activation of MYC, which in turn promotes cell-cycle progres-
sion via CCND2 (Bouchard et al., 2001). A recent study dem-
onstrated that IL-7–STAT5 signaling in these cells actively 
prevents Ig light chain gene recombination (Malin et al., 2010). 
The Ig light chain loci IL-7–STAT5–dependent pro– and large 
cycling pre–BII cells are in germline configuration, and the level 
of DNA damage (e.g., DSB) is low (Fig. S5, left). Activation of 
pre–B cell receptor signaling in large cycling pre–BII cells, how-
ever, induces down-regulation of the IL-7 receptor (Fig. 3 D), 
down-regulation of IL-7 responsiveness (Schebesta et al., 2002; 
Johnson et al., 2008), and ultimately dephosphorylation of 
STAT5 (Fig. 3 C). Dephosphorylation of STAT5 may either 
result from reduced IL-7 responsiveness (Schebesta et al., 2002; 
Johnson et al., 2008) or interference of the pre–B cell receptor 
signaling molecule SLP65 with JAK3–STAT5 signal transduc-
tion (Nakayama et al., 2009). Termination of IL-7R–JAK1–
STAT5 signaling leads to down-regulation of MYC-CCND2 
and, hence, loss of the “large cycling” phenotype of pre–BII 
cells. At the same time, loss of IL-7R–JAK1–STAT5 signaling 
allows transcriptional activation of BCL6, which leads to further 
transcriptional repression of MYC-CCND2 (Fig. 2 B; Ci et al., 
2009). The identification of MYC and CCND2 as transcrip-
tional targets of BCL6 can explain that expression of MYC and 
BCL6 are mutually exclusive at the transition from large cycling 
pre–BII cells (MYC+ BCL6) to small resting pre–BII cells 
(MYC BCL6+).
After productive VH-DJH recombination, pre–B cell re-
ceptor signaling induces up-regulation of IRF4/8 and other 
factors needed for Ig light chain gene rearrangement (Schebesta 
et al., 2002; Johnson et al., 2008). In consequence, de novo 
expression of BCL6 upon IL-7 withdrawal coincides with 
initiation of Ig light chain gene rearrangement. Recombina-
tion events at Ig light chain loci (V-J, KDE-J intron, and 
KDE-V at 2p12; V-J at 22q11) involve multiple DNA 
DSBs and induce activation of DNA damage response genes 
and checkpoint genes, including ARF, p21, and p27, which 
are all negatively regulated by BCL6 (Fig. 6, A–D). In the 
absence of BCL6, Ig light chain gene rearrangement leads to JEM VOL. 207, June 7, 2010 
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from eBioscience. For apoptosis analyses, annexin V, propidium iodide, and 
7-AAD were used (BD).
Affymetrix GeneChip analysis. Total RNA from cells used for microarray 
was isolated by RNeasy purification. Biotinylated cRNA was generated and 
fragmented according to the Affymetrix protocol and hybridized to 430 
mouse microarrays (Affymetrix). After scanning (GeneChip Scanner 3000 7G; 
Affymetrix) the GeneChip arrays, the generated data files were imported to 
BRB  Array  Tool  (available  at  http://linus.nci.nih.gov/BRB-ArrayTools.
html) and processed using the robust multi-array average algorithm for nor-
malization and summarization. To determine relative signal intensities, the ra-
tio of intensity for each sample in a probe set was calculated by normalizing to 
the mean value of grouped samples. Ratios were exported in Gene Cluster and 
visualized as a heatmap with Java Treeview. Microarray data are available from 
the Gene Expression Omnibus under accession nos. GSE21664 (IL-7 with-
drawal from pre–B cells) and GSE20987 (comparison of BCL6+/+ and 
BCL6/ BCR-ABL1–transformed pre–B cells).
ChIP on chip. Human B cell lymphoma OCI-Ly1 cells were fixed and 
washed, and chromatin was sheared to an average length of 600 bp. BCL6–
DNA complexes were immunoprecipitated using an anti-BCL6 polyclonal 
antibody (N3). Enrichment of known target genes was validated by quantita-
tive real-time PCR. ChIP products and their respective input genomic frag-
ments were amplified by ligation-mediated PCR as previously reported 
(Ranuncolo et al., 2007). QChIP was performed again at this stage for selected 
positive control loci to verify that the enrichment ratios were retained. The 
genomic products of two biological ChIP replicates were labeled with Cy5 
(for ChIP products) and Cy3 (for input), and cohybridized on custom-
designed genomic tiling arrays generated by NimbleGen Systems Inc. These 
high-density tiling arrays contain 50-residue oligonucleotides with an average 
overlap of 25 bases, omitting repetitive elements. Included in the arrays were 
the genomic region of the CDKN2A locus (Chr9:21950629–22003329) ac-
cording to the human genome May 2004 assembly. After hybridization, the 
relative enrichment for each probe was calculated as the signal ratio of ChIP to 
input. Peaks of enrichment for BCL6 relative to input were captured with a   
5-probe sliding window, and the results were uploaded as custom tracks into 
the University of California, Santa Cruz genome browser and graphically rep-
resented as histograms. The cutoff threshold is defined as 2.5 times the SD 
above the average relative enrichment on the entire array. Peaks involving 
five or more oligonucleotide probes above this threshold were consid-
ered positive hits.
QChIP. 3 × 107 cells were used for ChIP. Cells were double cross-linked 
with 1.5 mmol/liter EGS (Thermo Fisher Scientific) for 30 min, followed 
by 1% formaldehyde (Sigma-Aldrich) for 10 min at room temperature. They 
were lysed (1% Triton X-100, 150 mmol/liter NaCl, 20 mmol/liter Tris, 
pH 8, 0 and 1 mmol/liter EDTA) and sonicated using a sonicator (Branson 
Digital Sonifier 450) for 40 min. Cells were immunoprecipitated with rabbit 
polyclonal antibody to BCL6 (N3) and rabbit polyclonal antibody to -actin 
(H-196; Santa Cruz Biotechnology, Inc.) as a control. Eluted DNA was 
quantified by PCR (Opticon Engine 2; MJ Research) with the SYBR Green 
Kit (QIAGEN). Primers to confirm binding of BCL6 to the ARF (CD-
KN2A) promoter region are given in Table S3. Serial dilutions of input 
DNA were performed to assess the relative amount of product that was en-
riched after immunoprecipitation.
Clonality analysis and spectratyping of B cell populations. VH-DJH 
gene rearrangements from B cell populations were amplified using PCR prim-
ers specific for the J558 VH region gene together with a primer specific for the 
C constant region gene. Using a FAM-conjugated C constant region or a 
JH gene-specific primer in a run-off reaction, PCR products were labeled and 
subsequently analyzed on a capillary sequencer (ABI3100; Applied Biosystems) 
by fragment-length analysis. Sequences of primers used are given in Table S3.
Online supplemental material. Fig. S1 shows our sorting strategy for 
HPCs, pro–B and pre–BI cells, large cycling pre–BII cells (fraction C’), small 
A recombinant peptide containing the SMRT BBD along with a cell penetrat-
ing the TAT domain was able to block interaction of BCL6 with SMRT and 
N-CoR (Polo et al., 2004). Based on this initial work, a retro-inverso/fusogenic 
peptidomimetic molecule with superior potency and stability was developed 
(Cerchietti et al., 2009) and used for the BCL6 inhibition cell-culture experi-
ments described. RI-BPI represents a retro-inverso TAT-BBD-fusogenic pep-
tide (Cerchietti et al., 2009) and was synthesized by Biosynthesis, Inc. and 
stored lyophilized at 20°C until reconstituted with sterile water immediately 
before use. The purity determined by HPLC-MS was 95% or higher.
Retroviral transduction. Transfections of MSCV-based retroviral con-
structs encoding BCL6-IRES-GFP, MYC-IRES-GFP, SLP65-IRES-GFP, 
BCR-ABL1-IRES-GFP, BCR-ABL1-IRES-Neo, or Neo and GFP empty 
vector controls were performed using Lipofectamine 2000 (Invitrogen) with 
Opti-MEM media (Invitrogen). Retroviral supernatant was produced by 
cotransfecting 293FT cells with the plasmids pHIT60 (gag-pol) and pHIT123 
(ecotropic env; provided by D.B. Kohn, University of California, Los Ange-
les, Los Angeles, CA). Cultivation was performed in high glucose DMEM 
(Invitrogen) with GlutaMAX containing 10% fetal bovine serum, 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 25 mM Hepes, 1 mM sodium pyruvate, 
and 0.1 mM of nonessential amino acids. Regular media were replaced after 
16 h by growth media containing 10 mM sodium butyrate. After 8 h of in-
cubation, the media was changed back to regular growth media. 24 h later, 
the virus supernatant were harvested, filtered through a 0.45-µm filter, and 
loaded by centrifugation (2,000 g for 90 min at 32°C) two times on 50 µg/ml 
RetroNectin-coated nontissue 6-well plates. 2–3 × 106 pre–B cells were 
transduced per well by centrifugation at 500 g for 30 min and maintained 
overnight at 37°C with 5% CO2 before transferring into culture flasks.
V(D)J recombination reporter assay. For construction of the recombi-
nation reporter plasmid, a PCR fragment including both 5 and 3 RSS ampli-
fied from the vector pJH288 was ligated into the retroviral expression vector 
pMOWS containing a puromycin resistance gene for selection (Wossning et al., 
2006). GFP cDNA was ligated in between the RSS in reverse orientation. 
BCL6/ and wild-type BCR-ABL1+ pre–B cells were transduced with the 
RSS-GFP reporter retrovirus. 3 d after transduction, transduced cells were 
selected in the presence of 1 µg/ml puromycin for 5 d. At this time, no viable 
cells were detected in a nontransduced parallel culture.
Quantitative RT-PCR. Total RNA from cells was extracted using the 
RNeasy isolation kit from QIAGEN. cDNA was generated using a poly(dT) 
oligonucleotide and SuperScript III Reverse Transcriptase (Invitrogen). 
Quantitative real-time PCR was performed with the SYBRGreenER mix 
(Invitrogen) and a real-time PCR system (ABI7900HT; Applied Biosystems) 
according to standard PCR conditions. Primers for quantitative RT-PCR are 
listed in Table S3.
Western blotting. Cells were lysed in CelLytic buffer (Sigma-Aldrich) 
supplemented with 1% protease inhibitor cocktail (Thermo Fisher Scientific). 
10 µg of protein mixture per sample was separated on NuPAGE (Invitrogen) 
4–12% Bis-Tris gradient gels and transferred on polyvinylidene fluoride mem-
branes (Immobilion; Millipore). For the detection of mouse and human proteins 
by Western blotting, primary antibodies were used together with an immuno-
detection system (WesternBreeze; Invitrogen). The following antibodies were 
used: human BCL6 (clones D8 and N3; Santa Cruz Biotechnology, Inc.), 
mouse BCL6 (rabbit polyclonal; Cell Signaling Technology), ARF (4C6/4; 
Cell Signaling Technology), p53 (1C12; Cell Signaling Technology), global 
STAT5  (3H7;  Cell  Signaling  Technology),  and  phospho-Y694  STAT5 
(14H2; Cell Signaling Technology). Antibodies against -actin were used as 
a loading control (H4; Santa Cruz Biotechnology, Inc.).
Flow cytometry. Antibodies against mouse CD19 (1D3), B220 (RA3-6B2), 
c-kit (2B8), CD25 (7D4), CD43 (S7), IgM or  chain (R6-60.2 and II/41), 
IgD (11–26), and  light chains (187.1) as well as respective isotype controls 
were purchased from BD. Anti–mouse Sca-1 antibody (clone 177228) was 
obtained from R&D Systems and anti–mouse IL-7R (A7R34) was obtained 1220 BCL6 promotes pre–B cell self-renewal | Duy et al.
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resting pre–BII cells (fraction D), and immature B cells from the bone mar-
row of BCL6+/+ and BCL6/ mice. Fig. S2 shows survival and growth of 
IL-7–dependent pre–B cells from bone marrow of BCL6+/+ and BCL6/ 
mice under cell-culture conditions and cytoplasmic stainings for  chain ex-
pression in IL-7–dependent and BCR-ABL1–transformed pre–B cells from 
SLP65-deficient mice. Fig. S3 depicts induction of  light chain expression 
on BCR-ABL1–transformed pre–B cells from BCL6+/+ and BCL6/ mice. 
In addition, transformed BCL6+/+ and BCL6/ pre–B cells were trans-
duced with a reporter construct for V(D)J recombinase activity. STI571-
induced V(D)J recombinase activity was assayed along with  light chain 
expression and apoptosis (annexin V) by flow cytometry. Fig. S4 shows dif-
ferentiation and survival of RAG1+/+ and RAG1/ pre–B cells upon IL-7 
withdrawal and concomitant BCL6 inhibition. Fig. S5 presents a proposed 
scenario for the role of BCL6 during the transition from IL-7–dependent to 
–independent stages of B cell development. Table S1 presents a quantitative 
analysis of flow cytometry studies of BCL6+/+ and BCL6/ B cell precursor 
populations. Table S2 presents a detailed sequence analysis of junctional re-
gions within VH-DJH rearrangements in + immature B cells from the bone 
marrow and spleen of BCL6+/+ and BCL6/ mice. Table S3 lists sequences 
of  oligonucleotide  primers  used  for  clonality  and  spectratyping  analyses, 
quantitative RT-PCR, and QChIP. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20091299/DC1.
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